Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析

◆英語タイトル:Bio-Path Holdings Inc (BPTH) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH17139FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) and BP1002 (Liposomal Bcl2). Its prexigebersen (Liposomal Grb2 Antisense), is developed for the treatment of Acute Myeloid Leukemia (AML) and solid tumors. Bio-Path’s BP1002 (Liposomal Bcl2) is used for the treatment of lymphoma, leukemia, colon, prostate and breast cancers. The company’s proprietary liposomal delivery and antisense technology platform DNAbilize, is used to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path is headquartered in Bellaire, Texas, the US.

Bio-Path Holdings Inc Key Recent Developments

Apr 05,2021: Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
Mar 11,2021: Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting
Mar 10,2021: Bio-Path Holdings Reports Full Year 2020 Financial Results
Mar 03,2021: Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021
Feb 18,2021: Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock

This comprehensive SWOT profile of Bio-Path Holdings Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Bio-Path Holdings Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Bio-Path Holdings Inc – Key Information
Bio-Path Holdings Inc – Overview
Bio-Path Holdings Inc – Key Employees
Bio-Path Holdings Inc – Key Employee Biographies
Bio-Path Holdings Inc – Key Operational Heads
Bio-Path Holdings Inc – Major Products and Services
Bio-Path Holdings Inc – History
Bio-Path Holdings Inc – Company Statement
Bio-Path Holdings Inc – Locations And Subsidiaries
Bio-Path Holdings Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Bio-Path Holdings Inc – Business Description
Bio-Path Holdings Inc – Corporate Strategy
Bio-Path Holdings Inc – SWOT Analysis
SWOT Analysis – Overview
Bio-Path Holdings Inc – Strengths
Bio-Path Holdings Inc – Weaknesses
Bio-Path Holdings Inc – Opportunities
Bio-Path Holdings Inc – Threats
Bio-Path Holdings Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Bio-Path Holdings Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Bio-Path Holdings Inc, Key Information
Bio-Path Holdings Inc, Key Ratios
Bio-Path Holdings Inc, Share Data
Bio-Path Holdings Inc, Major Products and Services
Bio-Path Holdings Inc, History
Bio-Path Holdings Inc, Key Employees
Bio-Path Holdings Inc, Key Employee Biographies
Bio-Path Holdings Inc, Key Operational Heads
Bio-Path Holdings Inc, Other Locations
Bio-Path Holdings Inc, Subsidiaries
Bio-Path Holdings Inc, Key Competitors
Bio-Path Holdings Inc, SWOT Analysis
Bio-Path Holdings Inc, Ratios based on current share price
Bio-Path Holdings Inc, Annual Ratios
Bio-Path Holdings Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sino-Ocean Group Holding Limited:企業の戦略・SWOT・財務情報
    Sino-Ocean Group Holding Limited - Strategy, SWOT and Corporate Finance Report Summary Sino-Ocean Group Holding Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Changmao Biochemical Engineering Co., Ltd:企業の戦略・SWOT・財務情報
    Changmao Biochemical Engineering Co., Ltd - Strategy, SWOT and Corporate Finance Report Summary Changmao Biochemical Engineering Co., Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Fitbit Inc.:戦略・SWOT・企業財務分析
    Fitbit Inc. - Strategy, SWOT and Corporate Finance Report Summary Fitbit Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Zimmer Biomet Holdings Inc (ZBH):企業の財務・戦略的SWOT分析
    Zimmer Biomet Holdings Inc (ZBH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • SK Chemicals Co Ltd (006120):企業の財務・戦略的SWOT分析
    Summary SK Chemicals Co Ltd (SK Chemicals) is a provider of chemical and pharmaceutical products. The company offers pharmaceutical drugs to treat erectile dysfunction, arthritis, peptic ulcer, gastroesophageal reflux disease (GERD), cancer and to improve blood circulation. It manufactures green che …
  • Snam SpA (SRG):石油・ガス:M&Aディール及び事業提携情報
    Summary Snam SpA (Snam) is an integrated midstream energy company. The company, through its subsidiaries, carries out the regasification, transportation, storage and supply of natural gas. It transports and dispatches natural gas through a transportation network, a dispatch center, supervisory distr …
  • Embera NeuroTherapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Embera NeuroTherapeutics Inc (Embera) is a contract research company that discovers and develops new treatments. The company’s product includes EMB-001, a drug combination for the stress response system and specific brain functions that results in craving and improvement associated with thes …
  • BASF Corp-エネルギー分野:企業M&A・提携分析
    Summary BASF Corp (BASF), a subsidiary of BASF SE, is a chemical manufacturing company. Its product portfolio includes petrochemicals, monomers, intermediates, dispersions and pigments, care chemicals, nutrition and health products, paper chemicals, performance chemicals, catalysts, construction che …
  • Wienerberger AG:企業のM&A・事業提携・投資動向
    Wienerberger AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wienerberger AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Betta Pharmaceuticals Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Betta Pharmaceuticals Co Ltd (Betta Pharma) is a developer and manufacturer of drugs for treating cancer, cardiovascular diseases and diabetes. The company’s product includes conmana, a selective epidermal growth factor receptor tyrosine kinase inhibitor indicated for treating locally advanc …
  • MegaChips Corporation (6875):企業の財務・戦略的SWOT分析
    MegaChips Corporation (6875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Tizona Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tizona Therapeutics Inc (Tizona Therapeutics) is an immunology company which develops treatments for cancer and autoimmune disorders. Its lead product candidate anti-CD39 antibody inhibits the breakdown of excessive ATP released from dying tumor cells to immune suppressive adenosine leading …
  • Grupo Grana y Montero SAA (GRAMONC1):石油・ガス:M&Aディール及び事業提携情報
    Summary Grupo Grana y Montero SAA (Grana y Montero) is a group company that provides engineering and infrastructure services. The company’s business areas include engineering and construction, infrastructure development, real estate and technical services. It provides engineering procurement and con …
  • Pharmaniaga Berhad (PHARMA):企業の財務・戦略的SWOT分析
    Pharmaniaga Berhad (PHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Addnode Group AB (ANOD B):企業の財務・戦略的SWOT分析
    Summary Addnode Group AB (Addnode) is an information technology company that supplies software and services for construction, design, and product data information. The company's solutions include design management solutions, process management solutions, and product lifecycle management solutions, a …
  • Abano Healthcare Group Ltd (ABA):企業の財務・戦略的SWOT分析
    Summary Abano Healthcare Group Ltd (Abano Healthcare), formerly ElderCare New Zealand Ltd, is a healthcare service provider that offers dental, audiology, radiology and medical services. The company also operates business in community pathology and radiology sector; and healthcare markets such as ab …
  • Amgen Inc (AMGN):医療機器:M&Aディール及び事業提携情報
    Summary Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncol …
  • Porto Seguro SA:企業の戦略・SWOT・財務分析
    Porto Seguro SA - Strategy, SWOT and Corporate Finance Report Summary Porto Seguro SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Turboatom (TATM):企業の財務・戦略的SWOT分析
    Turboatom (TATM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Alliant Energy Corporation:企業の戦略・SWOT・財務分析
    Alliant Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Alliant Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆